DNLI
Price
$18.79
Change
+$0.52 (+2.85%)
Updated
Jan 15, 04:59 PM (EDT)
Capitalization
2.85B
46 days until earnings call
Intraday BUY SELL Signals
KROS
Price
$19.27
Change
-$0.26 (-1.33%)
Updated
Jan 15, 04:59 PM (EDT)
Capitalization
595M
48 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DNLI vs KROS

Header iconDNLI vs KROS Comparison
Open Charts DNLI vs KROSBanner chart's image
Denali Therapeutics
Price$18.79
Change+$0.52 (+2.85%)
Volume$54.59K
Capitalization2.85B
Keros Therapeutics
Price$19.27
Change-$0.26 (-1.33%)
Volume$5.05K
Capitalization595M
DNLI vs KROS Comparison Chart in %
View a ticker or compare two or three
VS
DNLI vs. KROS commentary
Jan 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and KROS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 16, 2026
Stock price -- (DNLI: $18.27 vs. KROS: $19.53)
Brand notoriety: DNLI and KROS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 72% vs. KROS: 38%
Market capitalization -- DNLI: $2.85B vs. KROS: $595M
DNLI [@Biotechnology] is valued at $2.85B. KROS’s [@Biotechnology] market capitalization is $595M. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileKROS’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • KROS’s FA Score: 0 green, 5 red.
According to our system of comparison, KROS is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 4 TA indicator(s) are bullish while KROS’s TA Score has 5 bullish TA indicator(s).

  • DNLI’s TA Score: 4 bullish, 5 bearish.
  • KROS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, KROS is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а +7.79% price change this week, while KROS (@Biotechnology) price change was +5.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.44%. For the same industry, the average monthly price growth was +2.31%, and the average quarterly price growth was +42.34%.

Reported Earning Dates

DNLI is expected to report earnings on Mar 02, 2026.

KROS is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (-0.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.85B) has a higher market cap than KROS($595M). DNLI YTD gains are higher at: 10.660 vs. KROS (-4.077). KROS has higher annual earnings (EBITDA): 68.8M vs. DNLI (-534.17M). DNLI has more cash in the bank: 848M vs. KROS (693M). KROS has less debt than DNLI: KROS (17.4M) vs DNLI (44.4M). KROS has higher revenues than DNLI: KROS (247M) vs DNLI (0).
DNLIKROSDNLI / KROS
Capitalization2.85B595M479%
EBITDA-534.17M68.8M-776%
Gain YTD10.660-4.077-261%
P/E RatioN/A12.52-
Revenue0247M-
Total Cash848M693M122%
Total Debt44.4M17.4M255%
FUNDAMENTALS RATINGS
DNLI: Fundamental Ratings
DNLI
OUTLOOK RATING
1..100
14
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
50
P/E GROWTH RATING
1..100
99
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DNLIKROS
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
72%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 11 days ago
82%
Bearish Trend 11 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
87%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signal:
Gain/Loss:
KROS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYMCX8.580.07
+0.82%
Royce Micro-Cap Consult
JTUAX18.770.12
+0.64%
JPMorgan US Small Company A
TSCGX19.42-0.02
-0.10%
Thrivent Small Cap Growth S
ETTGX133.07-0.99
-0.74%
Eaton Vance Tx-Mgd Growth 1.1 A
JGRJX37.38-0.51
-1.35%
JPMorgan Growth Advantage R2

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with RGNX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+0.88%
RGNX - DNLI
54%
Loosely correlated
-0.66%
BEAM - DNLI
53%
Loosely correlated
+2.49%
VIR - DNLI
53%
Loosely correlated
+8.08%
SYRE - DNLI
52%
Loosely correlated
+5.17%
CDXS - DNLI
51%
Loosely correlated
+4.09%
More

KROS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KROS has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KROS
1D Price
Change %
KROS100%
+0.15%
AXON - KROS
43%
Loosely correlated
-1.92%
DNLI - KROS
39%
Loosely correlated
+0.88%
ALT - KROS
39%
Loosely correlated
+4.24%
CLDX - KROS
39%
Loosely correlated
+1.58%
SPHDF - KROS
38%
Loosely correlated
N/A
More